Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

BACKGROUND: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical trials showed a benefit in progression free survival for gefitinib ver...

Descripción completa

Detalles Bibliográficos
Autores principales: Verduyn, S Cora, Biesma, Bonne, Schramel, Franz MNH, van der Scheer, Feike W, Langenfeld, Merel K, de Peuter, Maria A, Dingemans, Anne-Marie C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492197/
https://www.ncbi.nlm.nih.gov/pubmed/22963131
http://dx.doi.org/10.1186/1477-7525-10-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492197/
https://www.ncbi.nlm.nih.gov/pubmed/22963131
http://dx.doi.org/10.1186/1477-7525-10-108

Ejemplares similares